1Veeraraghavan S, Nicholson AG, Wells AU, et al. Lung fibrosis:new classifications and therapy. Curr Opin Rheumatol, 2001, 13:500-504.
2Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol, 2004, 16: 186-191.
3Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol,2003, 15: 748-755.
4MacDonald SLS, Rubens MB, Hansell DM, et al. Nonspecific interstitial pnermonia and usual interstitial pneumonia:comparative appearances and diagnostic accuracy of high-resolution computed tomography. Radiology, 2001, 221: 600-605.
5Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic sclerosis. Curr Opin Pulm Med, 2001, 7: 283-290.
6Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum, 1994, 37: 1283-1289.
7Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis, 1999, 58: 635-640.
8Selman M, Thannichal V J, Pardo A, et al. Idiopathic pulmonary fibrosis. Drugs, 2004, 64: 405-430.
9Palas I, Ioannidis JA, Malagari K, ct al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.J Rheumatol, 2002, 29: 298-304.
10Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease:a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. JRheumatol, 2002, 29: 2371-2378.
